A combination product is a medical product that brings together two or more distinct types of regulated components: a drug, a medical device, a biological product, or some mix of all three. These aren’t just products that happen to be used together. They are formally defined under federal regulation and must meet safety and quality standards that apply to each of their individual parts. If you’ve ever used a prefilled insulin pen, an asthma inhaler, or a drug-coated stent, you’ve used a combination product.
The Four Types of Combination Products
The FDA recognizes four configurations of combination products, each defined in federal regulation (21 CFR 3.2(e)). The differences come down to how the components are packaged and whether they can function independently.
- Single-entity products: Two or more components that are physically, chemically, or otherwise combined into one inseparable product. A drug-eluting stent is a classic example: a metal scaffold (device) coated with a medication (drug) that slowly releases to prevent the artery from narrowing again. You can’t separate the drug from the device.
- Co-packaged products: Two or more separate products packaged together as a unit. Think of an autoinjector kit that includes a prefilled syringe (device) and a vial of medication (drug) in one box. Each piece could theoretically exist on its own, but they’re sold together.
- Cross-labeled products (approved + new): A drug, device, or biologic packaged separately but labeled for use only with a specific, already-approved product. Both are required to achieve the intended effect, and approval of the new product would require changes to the labeling of the existing one.
- Cross-labeled products (both investigational): Two separately packaged investigational products, each labeled for use only with the other, where both are needed to work as intended.
The possible component pairings are drug/device, biologic/device, drug/biologic, or all three together (drug/device/biologic).
Common Everyday Examples
Combination products are more familiar than the regulatory language suggests. Metered-dose inhalers combine a bronchodilator drug with a device that aerosolizes it into your lungs. Prefilled epinephrine autoinjectors pair a life-saving drug with a spring-loaded delivery device. Transdermal patches embed a drug into an adhesive device that controls how much medication passes through your skin over time. Bone cement loaded with antibiotics merges a surgical device with a drug to fight infection at the implant site. Prefilled syringes containing a biologic therapy, like certain injectable treatments for autoimmune conditions, combine a biological product with a device designed for self-injection.
In each case, the drug or biologic wouldn’t reach the body effectively without the device, and the device would serve no therapeutic purpose without the drug or biologic.
How the FDA Decides Who Reviews It
The FDA doesn’t have a single office that handles all combination products. Instead, each combination product gets assigned to one lead center based on its “primary mode of action,” which is the single function of the product that provides its most important therapeutic effect.
If a product’s primary therapeutic value comes from the drug component, the Center for Drug Evaluation and Research typically takes the lead. If the biologic component drives the main benefit, the Center for Biologics Evaluation and Research leads. If the device component is most therapeutically important, the Center for Devices and Radiological Health oversees review. The lead center then coordinates with the other relevant centers as needed.
Sometimes neither mode of action is clearly more important than the other. When that happens, the FDA follows a set algorithm: it looks at which center handles products that raise similar safety and effectiveness questions, or, failing that, which center has the most expertise to evaluate the product’s most significant safety concerns.
The Request for Designation Process
Companies that are unsure which FDA center should review their product can submit a formal Request for Designation (RFD) to the FDA’s Office of Combination Products. This submission lays out the product’s components, its intended use, and how it works. The FDA then has 60 days from the filing date to issue a jurisdictional determination, telling the company which center will lead the review.
Before filing a formal RFD, companies can also submit a Pre-RFD to get informal guidance on jurisdictional questions. This step helps resolve ambiguity early before a company commits to a full regulatory application.
Quality and Manufacturing Standards
Combination products face a unique manufacturing challenge: they must comply with the quality system requirements that apply to each of their constituent parts. A drug-device combination, for example, needs to meet both the drug manufacturing standards and the device manufacturing standards. Federal regulation under 21 CFR Part 4 spells out how manufacturers can satisfy both sets of requirements for a single-entity or co-packaged product without duplicating effort.
This dual obligation exists because the risks associated with each component type are different. Drug manufacturing focuses on things like potency, purity, and contamination. Device manufacturing emphasizes design controls, mechanical reliability, and biocompatibility. A combination product has to get both right.
Why Safety Reporting Gets Complicated
After a combination product reaches the market, the company that holds the marketing authorization must follow safety reporting rules for every type of constituent part in the product. This can mean juggling multiple reporting timelines simultaneously.
If the product contains a device component, the company must file five-day reports for certain urgent events, malfunction reports, and correction or removal reports. If it contains a drug component, field alert reports and 15-day reports are required (though that 15-day window extends to 30 days if the product was authorized under a device application). Biological components trigger their own set of deviation reports and 15-day reports, with the same 30-day extension for device-authorized products.
When a serious injury or death is associated with a combination product, the company must share the information with any other applicant responsible for a constituent part within five calendar days. This cross-reporting requirement exists because different companies may hold separate authorizations for different parts of the combination, and each needs to know about safety signals promptly.
Use-Related Risks Unique to Combinations
One reason combination products receive extra regulatory scrutiny is that they can introduce risks that wouldn’t exist if either the drug or device were used alone. A standalone inhaler device has certain risks (dropping it, not sealing your lips properly). A standalone bronchodilator drug has its own risks (wrong dose, drug interactions). But when you combine them, new problems can emerge: the device might deliver an inconsistent dose, or the user might not coordinate the button press and inhalation correctly, turning a device-handling error into a medication error.
The FDA requires human factors engineering assessments for combination products that account for this layered risk. Critical tasks for a combination product are defined not just by the potential for device failure or medication error individually, but by the ways those failures can interact when the components are used together. A user error that would be minor with a standalone device could become serious when it causes the wrong amount of a potent drug to enter your body.